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Humoral alloreactivity has been recognized as a common cause of kidney transplant 
dysfunction. B-cell activation, differentiation, and antibody production are dependent 
on IL-21+CXCR5+follicular T-helper (Tfh) cells. Here, we studied whether belatacept, an 
inhibitor of the costimulatory CD28-CD80/86-pathway, interrupts the crosstalk between 
Tfh- and B-cells more efficiently than the calcineurin inhibitor tacrolimus. The suppressive 
effects of belatacept and tacrolimus on donor antigen-driven Tfh–B-cell interaction were 
functionally studied in peripheral blood mononuclear cells from 40 kidney transplant 
patients randomized to a belatacept- or tacrolimus-based immunosuppressive regimen. 
No significant differences in uncultured cells or donor antigen-stimulated cells were found 
between belatacept- and tacrolimus-treated patients in the CXCR5+Tfh cell generation 
and activation (upregulation of PD-1). Belatacept and tacrolimus in vitro minimally inhibited 
Tfh-cell generation (by ~6–7%) and partially prevented Tfh-cell activation (by ~30–50%). 
The proportion of IL-21+-activated Tfh-cells was partially decreased by in vitro addition of 
belatacept or tacrolimus (by ~60%). Baseline expressions and proportions of activated 
CD86+ B-cells, plasmablasts, and transitional B-cells after donor antigen stimulation did 
not differ between belatacept- and tacrolimus-treated patients. Donor antigen-driven 
CD86 upregulation on memory B-cells was not fully prevented by adding belatacept 
in vitro (~35%), even in supratherapeutic doses. In contrast to tacrolimus, belatacept 
failed to inhibit donor antigen-driven plasmablast formation (~50% inhibition vs. no inhi-
bition, respectively, p < 0.0001). In summary, donor antigen-driven Tfh-B-cell crosstalk is 
similar in cells obtained from belatacept- and tacrolimus-treated patients. Belatacept is, 
however, less potent in vitro than tacrolimus in inhibiting Tfh-cell-dependent plasmablast 
formation.
Keywords: belatacept, costimulatory blockade, follicular T-helper cells, immunoglobulins, plasmablasts, 
tacrolimus, transitional B-cells
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inTrODUcTiOn
B-cells and antibodies against the allograft are increasingly 
recognized to contribute to alloreactivity and subsequent graft 
failure after kidney transplantation under the currently used 
calcineurin inhibitor (CNI)-based immunosuppressive regimen 
(1–7). CD4+CXCR5+follicular T-helper (Tfh) cells are key media-
tors in B-cell activation, differentiation, and antibody production 
(8–12). Moreover, these cells infiltrate the allograft and colocalize 
with B-cells during acute rejection after kidney transplantation 
(13, 14). In alloreactivity, both Tfh- and B-cells are activated by 
the same antigen via their T- and B-cell receptor, respectively (15). 
The CD40-40L, CD28-CD80/86, and ICOS-ICOSL costimula-
tory pathways and the cytokines IL-6 and IL-21 are important 
in this Tfh–B-cell interaction and for B-cell differentiation into 
immunoglobulin-producing plasma cells (16–21).
Belatacept is a selective inhibitor of the CD28-CD80/86 
pathway and subsequently interrupts Tfh–B-cell interaction 
(21, 22). In animal transplant models, belatacept, or the lower 
affinity version abatacept (CTLA4 Immunoglobulin), inhibited 
germinal center formation, clonal B-cell expansion, IL-21 pro-
duction, and the development of donor-specific anti-human leu-
kocyte antigen antibodies (DSA) (14, 23). These findings were in 
line with observations from a large randomized, controlled trial 
in kidney transplant patients where the belatacept-based regimen 
resulted in a significantly lower prevalence of DSA than the cyclo-
sporine A (CsA)-based regimen at 7 years after transplantation: 
4.6 vs. 17.8%, respectively (24). However, in all these clinical 
studies, belatacept was combined with other immunosuppressive 
drugs: in the BENEFIT and BENEFIT-EXT trials belatacept was 
combined with mycophenolate mofetil (MMF) and prednisone, 
and in the animal studies, belatacept was combined with either 
sirolimus or T-cell-depleting antibodies (14, 23–25).
Contradictory effects of tacrolimus on B-cell activation, 
proliferation, and differentiation have been reported (26–28) 
because tacrolimus only inhibits calcium-influx dependent and 
not calcium-independent, B- and T-cell activation (27, 29). 
This calcineurin-mediated activation is dependent on the type 
of stimulus (26, 28, 29). B-cell activation can thus be prevented 
by calcineurin-inhibition in an antigen-dependent manner. The 
effect of tacrolimus on donor antigen-stimulated Tfh–B-cell 
interaction is unknown in kidney transplantation.
In addition to the in  vivo animal studies and clinical data 
that suggest belatacept effectively inhibits the humoral immune 
response specific for donor antigen (14, 23, 24), this class of 
immunosuppressive agents may also favor a more regulatory 
rather than effector alloreactive B-cell activity by enhancing 
the survival of transitional B-cells over memory B-cells in the 
long term (30). Theoretically, this may reduce rejection risk 
(15, 30–34).
So far no studies have been conducted which compared the 
effects of belatacept to tacrolimus, on Tfh–B-cell interaction 
in kidney transplantation. We hypothesized that belatacept 
more efficiently interrupts Tfh-B-cell crosstalk than tacrolimus. 
Therefore, we compared (i) the frequencies of Tfh and B-cell sub-
sets between belatacept- and tacrolimus-treated patients; (ii) the 
in vitro donor antigen-driven Tfh–B-cell interaction in peripheral 
blood mononuclear cells (PBMCs) obtained from belatacept- and 
tacrolimus-treated kidney transplant patients; and (iii) the iso-
lated the effects of additional belatacept and tacrolimus in vitro on 
donor antigen-driven Tfh–B-cell interaction in PBMCs obtained 
from the same patients.
MaTerials anD MeThODs
study Population and Materials
Materials were collected from 40 kidney transplant patients and 
their donors who participated in a prospective, randomized-
controlled trial (approved by the Medical Ethical Committee 
of the Erasmus MC, University Medical Centre Rotterdam; 
MEC-2012-42, EUDRACT CT # 2012-003169-16). After written 
informed consent, patients were included and randomized to a 
tacrolimus-based (control) or belatacept-based (experimental) 
immunosuppressive regimen. For in- and exclusion criteria, 
refer to Table S1 in Supplementary Material. All procedures were 
in accordance with the ethical standards of the Declaration of 
Istanbul (35). In short, both groups received basiliximab induc-
tion therapy (Simulect®, Novartis, Basel, Switzerland), followed 
by maintenance therapy with MMF and prednisolone, which was 
tapered to 5 mg by month 3 after transplantation. Maintenance 
therapy with tacrolimus (Prograf®, Astellas Pharma, Tokyo, 
Japan) was adjusted to predose levels of 5–10  ng/mL, while 
belatacept (Nulojix®, Bristol-Meyers Squibb, NYC, NY, USA) was 
dosed according to bodyweight (Less-Intensive regimen of the 
BENEFIT trials) (36).
Lithium heparin blood was collected from patients 1  day 
before transplantation and 3  months after transplantation or 
during clinically suspected acute rejection before any additional 
anti-rejection therapy was given. All samples were processed 
within 24 h of withdrawal. If patients had a biopsy-proven acute 
rejection (BPAR) (2) materials of that time point were used 
instead of their materials of 3  months after transplantation. 
Lithium heparinized blood from donors was collected 1  day 
before transplantation. PBMCs were isolated from blood using 
the Ficoll density isolation method.
Mixed lymphocyte reactions (Mlrs)
Patients PBMCs obtained after transplantation were thawed 
and used in MLRs. PBMCs were obtained 3 months after trans-
plantation in stable, non-rejecting patients or before additional 
antirejection therapy was given in rejecting patients. Live cells 
were counted under a light microscope and distinguished from 
dead cells with Trypan Blue. Per patient ~5 ×  105 uncultured 
PBMCs were stained for phenotypical analyses. A total of 5 × 104 
patients’ PBMCs/well (in a 96-wells plate) were stimulated for 
7  days at 37°C with 5  ×  104 carboxyfluorescein succinimidyl 
ester (CFSE)-labeled, irradiated donor PBMCs (40 Gy) in RPMI 
1640 + 10% heat-inactivated fetal bovine serum. Half of patients’ 
PBMCs were incubated for 1 h with clinically therapeutic concen-
trations of belatacept (10 μg/mL) (37) or tacrolimus (10 ng/mL), 
dependent on the randomization group, before donor antigen 
was added. After the donor antigen was added, these amounts of 
immunosuppressive drugs remained in the culture for the whole 
period of 7 days. At the end of day 6, 100 µL supernatant per well 
FigUre 1 | Different comparisons made in conducted studies (example 
figure). All figures in this manuscript comprise seven different comparisons. In 
this example, the proportion of CXCR5+ cells within CD4+ T-cells was used. 
In the left column (“in vivo drug”), the proportions of studied cell populations 
(see Flow Cytometry and Materials and Methods) were compared between  
(i) belatacept- and tacrolimus-treated patients in uncultured, unstimulated 
peripheral blood mononuclear cells (PBMCs); (ii) belatacept- and tacrolimus-
treated patients in 7-day donor antigen-stimulated PBMCs; (iii) uncultured, 
unstimulated PBMCs and 7-day donor antigen-stimulated PBMCs in 
belatacept-treated patients; and (iv) uncultured, unstimulated PBMCs and 
7-day donor antigen-stimulated PBMCs in tacrolimus-treated patients. In the 
right column (“Additional in vitro drug”), the relative inhibition by additional 
in vitro belatacept or tacrolimus is depicted by “v” and “vi”, respectively, in 
this example figure. If the median relative inhibition is significantly smaller than 
0, the in vitro drug significantly decreases the proportion of the studied cell 
type. Per cell type, the relative inhibitions were compared between belatacept 
and tacrolimus in vitro. This is depicted by “vii” in this example figure. Refer to 
Figure 2B for the population used in this example (proportion of CXCR5+ 
within CD4+ T cells).
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was harvested and stored at −20°C. Subsequently, Monensin and 
Brefeldin (GolgiStop and GolgiPlug, BD Biosciences, Franklin 
Lakes, NJ, USA) were added for 16 h over night in a concentration 
of 1:1,500 and 1:1,000, respectively, to allow the measurement of 
intracellularly accumulated cytokines in PBMCs.
Refer to Figure  1 for the different comparisons made in 
our study. Proportions of studied cell populations (see Flow 
Cytometry) were compared between:
 (i) belatacept- and tacrolimus-treated patients in uncultured, 
unstimulated PBMCs;
 (ii) belatacept- and tacrolimus-treated patients in 7-day donor 
antigen-stimulated PBMCs;
 (iii) uncultured, unstimulated PBMCs and 7-day donor antigen-
stimulated PBMCs in belatacept-treated patients;
 (iv) uncultured, unstimulated PBMCs and 7-day donor antigen-
stimulated PBMCs in tacrolimus-treated patients.
Patient PBMCs obtained 1  day before transplantation were 
also cultured with donor antigen in the same way to investi-
gate whether PBMCs obtained from an immunosuppressed 
environment reacted differently on donor antigen compared to 
PBMCs before any immunosuppression was given.
Post-transplant PBMCs obtained from three belatacept-treated 
and three tacrolimus-treated patients were used in MLRs to 
study the CD40-CD40L, PD1-PDL1, and ICOS-ICOSL interac-
tion during costimulation blockade by belatacept 10  µg/mL or 
calcineurin-inhibition by tacrolimus 10  ng/mL. MLRs were 
conducted as described above, only with 5 × 104 CD3 and CD19-
depleted irradiated donor PBMCs instead of CFSE-labeled donor 
PBMCs. The same methods were used in six independent MLRs 
of healthy controls’ PBMCs to determine free CD80/86 expres-
sion after allo-antigen stimulation in the presence of various 
concentrations of belatacept (0–1,000  µg/mL) or tacrolimus 
(0–100 ng/mL).
cFse labeling of PBMcs
To distinguish between patient and donor PBMCs in the MLRs, 
donor PBMCs were labeled with the cell-permeable, intracellular 
linker CFSE (Thermo Fisher Scientific, Waltham, MA, USA), 
according to manufacturer’s manual. CFSE-labeled donors’ 
PBMCs expressed as median fluorescence intensity (MFI) >104 
on the FITC channel.
cocultures of isolated Follicular T-helper 
(Tfh) cells and Memory B-cells (13, 38)
CD3+CD4+CXCR5+ T-cells and CD19+CD27+ B-cells from three 
healthy controls and three patients before transplantation were 
isolated using a FACSAria II 4L SORP™ (BD Biosciences). From 
both populations 2 × 104 cells/well were cocultured for 7 days at 
37°C with 4 × 104 40 Gy irradiated CD3/CD19-depleted, allogeneic 
PBMCs. Half of the wells were spiked with belatacept 10 µg/mL 
or tacrolimus 10  ng/mL. After 7  days coculture, supernatants 
were collected and stored at −20°C until analysis, and the pro-
portion of memory B-cells that differentiated into CD27+CD38++ 
plasmablasts was measured.
Flow cytometry
For a complete overview of the monoclonal antibodies used, see 
Table S2 in Supplementary Material. Follicular T-helper (Tfh) cells 
were defined as CD3+CD4+CXCR5+ T lymphocytes and classified 
as activated or resting by their expression of the activation marker 
and coinhibitor PD-1 (39, 40). Tfh-cell generation was defined as 
an increase in the proportion of CXCR5+ within CD4+ T-cells; 
Tfh-cell activation comprised the increase in the proportion of 
PD-1+ within CD4+CXCR5+ T-cells; and the generation of acti-
vated Tfh-cells was equivalent to an increase in the proportion of 
CXCR5+PD-1+ within CD4+ T-cells. The characteristic Tfh-cell 
cytokine IL-21 was determined in donor antigen-stimulated 
PBMCs in the presence or absence of belatacept or tacrolimus.
Within CD19+ B-cells, we distinguished CD27− naïve B-cells, 
CD27+ memory B-cells, CD24+CD38++ transitional B-cells, and 
CD27+CD38++ plasmablasts. Free CD86 expression on B-cells 
was measured on donor antigen-stimulated PBMCs by using an 
antibody that is competitive with belatacept for CD86 but binds 
with lower affinity (41). Expressions of the immune regulatory 
cytokine IL-10 in transitional B-cells and of the aggressive effector 
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cytokine TNFα in plasmablasts were also assessed after 7 days of 
donor antigen stimulation.
elisa for igM and igg3 Measurements
IgM concentrations in supernatants from all cell cultures were 
determined by ELISA. A calibration curve using human IgM 
1.6–100 ng/mL (Sigma-Aldrich, St. Louis, MO, USA) was used 
to quantify results. All experiments were performed in duplo 
(medians were used for end result). Supernatants were diluted, if 
necessary, to fit within the measurements of the calibration curve. 
Measurements <1.6 ng/mL were considered negative. IgG3 con-
centrations were measured in the same way using an ELISA-kit 
with a calibration curve of 4.4–200 ng/mL (Affymetrix/eBiosci-
ence, Santa Clara, CA, USA).
single Bead luminex assay
DSA were measured in (14–150×) concentrated culture super-
natants using the Single Antigen beads mix from the LABScreen 
Single Antigen class II kit (Thermo Fisher, Waltham, MA, USA) 
(13). Microbeads were analyzed with a Luminex LabscanTM 100 
analyzer using the Luminex 100IS software and analyzed using 
the HLA Fusion 3.0 software. All samples fulfilled the quality 
criteria for reactivity of the control beads.
calculation of the relative inhibition
The relative inhibition was used to account for inter-patient 
variability in the response to donor antigen (Figure 1, “additional 
in vitro” column). The relative inhibition by additional in vitro 
belatacept or tacrolimus was calculated for the donor antigen-
driven Tfh-cell generation, Tfh-cell activation, and the genera-
tion of activated Tfh-cells as well as for the donor antigen-driven 
intracellular IL-21 by activated Tfh-cells and the formation of 
IL21+ activated Tfh-cells. The relative inhibition by the in vitro 
drugs was also assessed for the upregulation of CD86 on naïve 
and memory B-cells, the formation of plasmablasts and their 
IgM production, and the transitional B-cell survival. For these 
calculations, the proportions of aforementioned cell subsets after 
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If the median relative inhibition is significantly smaller than 
0, the in vitro drug significantly decreases the proportion of the 
studied cell type (Figure  1, comparison “v” and “vi”). Per cell 
type, the relative inhibitions were compared between belatacept 
and tacrolimus in vitro (Figure 1, comparison “vii”).
statistical analyses
Proportions of cell subsets in uncultured or donor antigen-
stimulated PBMCs were compared between the belatacept and 
tacrolimus group using the Mann–Whitney U test (Figure 1, com-
parisons “i” and “ii”) as well as baseline characteristics that were 
continuous variables. Baseline characteristics that were categorical 
variables were compared with the Fisher’s exact test. Proportions 
of cell subsets between uncultured and donor antigen-stimulated 
PBMCs were compared using the Wilcoxon signed rank test 
(Figure 1, comparisons “iii” and “iv”). The median relative inhibi-
tion was compared to a theoretical mean of 0 (=no inhibition) with 
the Wilcoxon signed rank test to determine if the inhibition by the 
in vitro drug was statistically significant (Figure 1, comparisons 
“v” and “vi”). The relative inhibitions by in vitro belatacept and 
in vitro tacrolimus were compared using the Mann–Whitney U 
test (Figure 1, comparison “vii”).
Multivariable linear regressions were used to examine the 
in  vitro effects of belatacept compared to tacrolimus on donor 
antigen-activated Tfh and B-cell subsets, adjusted for confound-
ers [presence of in vitro added drugs (present vs. absent), time 
point (after vs. before transplantation), and BPAR (PBMCs 
obtained during rejection vs. 3  months after transplantation)]. 
To avoid multiple testing errors, only cell subsets in which the 
relative inhibition significantly differed between belatacept and 
tacrolimus in vitro were included for these analyses.
SPSS Statistics 21.0 (IBM, Armonk, NY, USA) was used for sta-
tistical analyses. Unless mentioned otherwise, medians (+range) 
are given for continuous variables, and numbers (+proportions) 
are given for categorical variables. p-Values with a two-sided α  
of <0.05 were considered statistically significant.
resUlTs
study Population
No significant differences were observed with regard to baseline 
characteristics between the two treatment groups (Table S3 in 
Supplementary Material).
The effects of Belatacept and Tacrolimus 
on Follicular T-helper (Tfh) cells
Tfh-Cell Generation and Activation (CXCR5 and PD-1 
Upregulation)
Refer to Figure 1 (example figure using the data from Figure 2B) 
for the different comparisons made in our study for the different 
cell subsets (more details in Section “Materials and Methods”). 
Results start from Figure  2. The surface expression of the Tfh 
marker CXCR5 and the activation marker PD-1 were determined 
on CD4+ Tfh cells (Figure 2).
Baseline expression of CXCR5 on CD4+ T-cells in uncultured 
PBMCs was comparable between belatacept- and tacrolimus-
treated patients (Figure 2B, “in vivo drug” column). Following 
donor antigen stimulation, Tfh-cell generation, defined by the 
expression of CXCR5 on CD4+ T-cells, increased~3- to 4-fold 
in PBMCs obtained from belatacept- and tacrolimus-treated 
patients, p < 0.001 and p < 0.01, respectively (Figure 2B, “in vivo 
drug” column). This process was inhibited when the samples were 
spiked in vitro by adding tacrolimus and belatacept. The relative 
inhibition of Tfh-cell generation, however, was similar between 
belatacept and tacrolimus: −6.3% (−56.6 to +3.3%), p < 0.001, by 
FigUre 2 | Continued
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FigUre 2 | Continued  
No differences between belatacept and tacrolimus in vivo or in vitro on donor antigen-driven follicular T-helper (Tfh) cell formation and activation in cultured peripheral 
blood mononuclear cells (PBMCs). Two typical examples are depicted for CXCR5 and PD-1 expression on Tfh cells in uncultured PBMCs and after 7 days of donor 
antigen stimulation, in the presence or absence of belatacept and tacrolimus (a). Follicular T-helper (Tfh) cells were distinguished from non-Tfh-cells by surface 
CXCR5 expression, while activated cells were defined by surface PD-1 expression. Donor PBMCs were discriminated by carboxyfluorescein succinimidyl ester 
labeling them prior to the mixed lymphocyte reaction and gating them out after. The proportions are depicted of CXCR5+ within CD4+ T-cells (B); PD-1+ within 
CD4+CXCR5+ T-cells (c); and CXCR5+PD-1+ within CD4+ T-cells (D). In the graphs in the “In vivo drug” column, proportions of aforementioned cell populations were 
compared (i) between belatacept- and tacrolimus-treated patients in uncultured, unstimulated PBMCs; (ii) between belatacept- and tacrolimus-treated patients in 
7-day donor antigen stimulated PBMCs; (iii) between uncultured, unstimulated PBMCs and 7-day donor antigen stimulated PBMCs in belatacept-treated patients; 
and (iv) between uncultured, unstimulated PBMCs and 7-day donor antigen stimulated PBMCs in tacrolimus-treated patients. Every dot represents PBMCs of a 
single patient. In the graphs in the “additional in vitro drug” column the relative inhibitions by additional in vitro belatacept and tacrolimus are depicted for 
aforementioned cell populations in the same belatacept- and tacrolimus-treated patients. The proportions of these cell populations after donor antigen stimulation in 
the absence of in vitro drugs are set to 0. The median relative inhibitions by belatacept and tacrolimus were tested against a theoretical median of 0. Asterisks below 
the boxes depict the p-values of these tests. The relative inhibitions were compared between belatacept and tacrolimus in vitro. Lines in boxes represent medians, 
borders of boxes represent 25th and 75th percentiles, and error bars present 10th and 90th percentiles. Every box represents cultures of PBMCs obtained from 
n = 20 belatacept-treated or n = 20 tacrolimus-treated patients. **p < 0.01, ***p < 0.001, NS, not significant.
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belatacept and −7.0% (−26.4 to +3.3%), p < 0.01, by tacrolimus 
(Figure 2B, “additional in vitro drug” column).
The expression of PD-1 on CD4+CXCR5+ T-cells in uncultured 
PBMCs was similarly low in belatacept- and tacrolimus-treated 
patients (medians 1.3 and 1.5%, respectively; Figure 2C, “in vivo 
drug” column). Tfh-cells of belatacept- and tacrolimus-treated 
patients were significantly activated after CD4+ T-cells donor 
antigen stimulation, i.e., a significant increase of PD-1 expres-
sion on CXCR5+ was observed. The relative inhibition of Tfh-cell 
activation was −27.5% (−74.0 to +2.3%), p < 0.001, by belatacept 
and −48.4% (−80.0 to 16.7%), p < 0.001, by tacrolimus, inhibi-
tion by belatacept vs. tacrolimus; p = 0.13 (Figure 2C, “additional 
in vitro drug” column).
The proportion of CXCR5+PD-1+ double-positive CD4+ 
T-cells was negligible in uncultured PBMCs from belatacept- and 
tacrolimus-treated patients (Figure 2D, “in vivo drug” column). 
The generation of activated Tfh-cells (defined by an increase of 
the proportion of CXCR5+PD-1+ double-positive CD4+ T-cells) 
was 1.1% (0.4–18.1%) in donor antigen-stimulated PBMCs 
from belatacept-treated patients and 1.6% (0.6–4.1%) in those 
from tacrolimus-treated patients. These proportions were not 
significantly different. The generation of activated Tfh-cells was 
inhibited by both belatacept and tacrolimus in vitro (Figure 2D, 
“additional in  vitro drug” column): the relative inhibition was 
−28.8% (−74.3 to −2.1%), p < 0.001 by belatacept, and −32.9% 
(−79.4 to +17.5%) by tacrolimus, p < 0.001.
Tfh Cell Function (Intracellular IL-21 Production)
As described previously, “activated Tfh-cells” were defined as 
Tfh-cells that upregulated PD-1 after donor antigen stimulation 
and “non-activated Tfh-cells” were defined as Tfh-cells that failed 
to upregulate PD-1 after donor antigen stimulation. IL-21, a key 
cytokine in Tfh–B-cell interaction, and subsequent B-cell differen-
tiation into immunoglobulin-producing plasma cells, was assessed 
in Tfh-cells (Figure 3). The donor antigen-stimulated IL-21 pro-
duction was highest in activated Tfh-cells (Figure 3B). The propor-
tions of IL21+-activated Tfh-cells within CD4+ T-cells were similar 
between donor antigen-stimulated PBMCs from the belatacept and 
tacrolimus groups (Figure 3C, “in vivo drug” columns). The total 
proportion of IL21+-activated Tfh-cells was partially decreased 
by belatacept and tacrolimus in vitro. The relative inhibition was 
−55.0% (−79.0 to +28.6%), p <  0.01, in the presence of belata-
cept and −57.7% (−94.1 to +8.7%), p < 0.001, in the presence of 
tacrolimus (Figure  3C, “in  vivo drug” columns). No differences 
between the inhibition by belatacept and tacrolimus were observed 
(Figure 3C, “additional in vitro drug” column). When we focused 
on the remaining activated Tfh-cells in the presence of in  vitro 
drugs, a substantial proportion could still produce IL-21. Even 
though the relative inhibitions of intracellular IL-21 production 
were not significantly different between belatacept and tacrolimus 
in vitro, only the latter (minimally) inhibited IL-21 production by 
activated Tfh-cells: relative inhibition −17.3% [−71.2 to + 52.9%, 
p < 0.05 (Figure 3D, “additional in vitro drug” column)].
Summary of the Effects of Belatacept and  
Tacrolimus on Tfh-Cells
Belatacept and tacrolimus minimally inhibited Tfh-cell genera-
tion and partially prevented Tfh-cell activation. The proportion 
of IL-21+-activated Tfh-cells was not completely diminished by 
in vitro addition of belatacept or tacrolimus. Thus, the remaining 
activated Tfh-cells have the potential capacity to provide B-cell 
help. Next, we tested the immunosuppressive effects of both 
agents on B-cell activation and functional Tfh-B-cell crosstalk.
The effects of Belatacept and Tacrolimus 
on B-cells
B-Cell Activation (CD86 Upregulation)
Part of the activation of B-cells and their ability to proliferate, 
differentiate, and function as antigen-presenting cells is reflected 
not only by their (free) CD86-expression but also by the expres-
sion of CD40 and ICOS-L. Here, the efficacy of belatacept was 
determined by means of B-cell activation, i.e., the free expression 
of CD86, which was measured on naïve CD19 +  CD27− and 
memory CD19+CD27+ B-cells (in proportions and MFIs), using 
tacrolimus as control (Figure  4). The expression of CD40 and 
ICOS-L on B-cells in the presence of belatacept is described in 
section “The Effect of Belatacept and Tacrolimus on Redundant 
Co-Stimulatory Pathways.”
CD86 expression was almost absent on naïve B-cells and low on 
memory B-cells in unstimulated uncultured PBMCs (Figure 4B, 
FigUre 3 | IL-21 production by remaining activated follicular T-helper (Tfh) cells was not inhibited by belatacept in vitro. A typical example is depicted for the 
intracellular IL-21 production after donor antigen stimulation in non-activated and activated Tfh-cells (CXCR5+PD-1− and CXCR5+PD-1+ CD4+ T-cells, respectively)  
in the presence and absence of belatacept (a). The proportions of IL-21+ cells within non-activated and activated Tfh-cells were compared after 7 days of donor 
antigen stimulation of peripheral blood mononuclear cells (PBMCs) obtained from both belatacept- and tacrolimus-treated patients (B). The proportions of 
IL21+-activated Tfh-cells within CD4+ T-cells (c) and the proportions of IL-21+ cells within activated Tfh-cells (D) were compared between 7-day donor antigen-
stimulated PBMCs obtained from the belatacept and tacrolimus group (“in vivo” column), as well as the relative inhibitions by in vitro addition of belatacept or 
tacrolimus (“additional in vitro” column). In the graphs in the “In vivo drug” columns, every dot represents PBMCs of a single patient. In the graphs in the “additional 
in vitro drug” columns, the relative inhibitions by additional in vitro belatacept and tacrolimus are depicted for aforementioned cell populations in the same 
belatacept- and tacrolimus-treated patients. The proportions of these cell populations after donor antigen stimulation in the absence of in vitro drugs are set to 0. 
The median relative inhibitions by belatacept and tacrolimus were tested against a theoretical median of 0. Asterisks below the boxes depict the p-values of these 
tests. The relative inhibitions were compared between belatacept and tacrolimus in vitro. Lines in boxes represent medians, borders of boxes represent 25th and 
75th percentiles, error bars present 10th and 90th percentiles. Every box represents cultures of PBMCs obtained from n = 20 belatacept-treated or n = 20 
tacrolimus-treated patients. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, NS, not significant.
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“in  vivo” columns). No differences were observed between 
belatacept- or tacrolimus-treated patients. After donor antigen 
stimulation, both the proportions of CD86+ B-cells, as well as the 
expression of CD86 (MFIs) significantly increased on both naïve 
and memory B-cells (Figure 4B, “in vivo” columns). These were 
not different between the belatacept and tacrolimus group.
Despite the selective binding of belatacept to CD86 (22), 
the upregulation of CD86 was not completely blocked by the 
in vitro addition of belatacept. The relative inhibition of CD86 
upregulation (proportion) by belatacept was −55.2% (−85.7 
to −18.8%), p <  0.001, on naïve B-cells and −35.5% (−63.9 to 
+0.2%), p < 0.001, on memory B-cells (Figure 4B, “additional 
in vitro drug”). The relative inhibition of CD86 upregulation on 
naïve and memory B-cells was significantly more by belatacept 
than by tacrolimus in vitro, p < 0.05. MFIs of CD86 on naïve and 
memory B-cells were significantly decreased by both belatacept 
and tacrolimus in vitro (Figure 4B, “additional in vitro drug”). 
The relative inhibitions of CD86 MFIs were comparable between 
belatacept and tacrolimus.
To determine if the residual B-cell activation in the presence 
of immunosuppressive drugs was dose-dependent, the relative 
inhibitions by belatacept and tacrolimus were measured in 
the presence of supratherapeutic concentrations. Even in the 
presence of supratherapeutic concentrations of belatacept, 
membrane CD86 expression on allo-antigen-stimulated B-cells 
was still detectable (Figure S1 in Supplementary Material): the 
relative inhibition by 1,000 µg/mL belatacept (100× higher than 
the therapeutic concentration) was −72.4% (−86.5 to −19.7%), 
p < 0.05, in naïve B-cells and −43.2% (−53.9 to −7.4%), p < 0.05, 
in memory B-cells.
FigUre 4 | Donor antigen-stimulated CD86 upregulation on B-cells is only partially blocked by belatacept in vitro. Two typical examples are depicted for the 
free CD86 expression after 7 days of donor antigen stimulation on naïve (CD27−) and memory (CD27+) CD19+ B-cells, in the presence and absence of 
belatacept or tacrolimus (a). The proportions are depicted of CD86+cells within naïve and memory B-cells as well as the median fluorescence intensities (MFIs) 
of CD86 within naïve and memory B-cells (B). In the graphs in the “In vivo drug” columns, proportions and MFIs of aforementioned cell populations were 
compared (i) between belatacept- and tacrolimus-treated patients in uncultured, unstimulated PBMCs; (ii) between belatacept- and tacrolimus-treated patients 
in 7-day donor antigen stimulated PBMCs; (iii) between uncultured, unstimulated PBMCs and 7-day donor antigen stimulated PBMCs in belatacept-treated 
patients; and (iv) between uncultured, unstimulated PBMCs and 7-day donor antigen stimulated PBMCs in tacrolimus-treated patients. Every dot represents a 
single culture of PBMCs. In the graphs in the “additional in vitro drug” columns, the relative inhibitions by additional in vitro belatacept and tacrolimus are 
depicted for aforementioned cell populations in the same belatacept- and tacrolimus-treated patients. The proportions or MFIs of these cell populations after 
donor antigen stimulation in the absence of in vitro drugs are set to 0. The median relative inhibitions by belatacept and tacrolimus were tested against a 
theoretical median of 0. Asterisks below the boxes depict the p-values of these tests. The relative inhibitions were compared between belatacept and tacrolimus 
in vitro. Lines in boxes represent medians, borders of boxes represent 25th and 75th percentiles, error bars present 10th and 90th percentiles. Every box 
represents cultures of PBMCs obtained from n = 20 belatacept-treated or n = 20 tacrolimus-treated patients. *p < 0.05, ***p < 0.001, ****p < 0.0001, NS, not 
significant.
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Since belatacept binds CD80 with much higher affinity than 
CD86 (22, 41), the residual surface expression of CD80 was low on 
activated naïve and memory B-cells in the presence of the different 
doses of belatacept (Figure S1 in Supplementary Material): The 
relative inhibition by 1,000 µg/mL belatacept was −90.2% (−97.5 
to −75.4%), p <  0.05, in naïve B-cells and −85.0% (−95.1 to 
−57.3%), p < 0.05, in memory B-cells. CD80 expression on B-cells 
was not significantly decreased in the presence of tacrolimus.
FigUre 5 | Continued
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B-Cell Differentiation (Plasmablast Formation)
To study the effect of belatacept and tacrolimus on the antigen-
dependent Tfh–B-cell interaction, differentiation of B-cells into 
plasmablasts was measured in donor antigen-activated PBMCs 
obtained after transplantation (Figure 5).
The proportions of plasmablasts were equally low in PBMCs 
from belatacept- and tacrolimus-treated patients (Figure  4B, 
“in  vivo drug” column). Plasmablast formation was significant 
after donor antigen stimulation in PBMCs from the belatacept 
group [8.8% (1.0–20.7%), p <  0.001] and from the tacrolimus 
group [13.1% (1.9–37.6%), p <  0.001], belatacept vs. tacroli-
mus group, p =  0.10. Only tacrolimus significantly inhibited 
plasmablast formation with a relative inhibition of −50.5% 
(−89.7 to −8.2%), p <  0.0001 (Figure  5B, “additional in  vitro 
drug” column). Belatacept failed to inhibit this alloreactive 
process in PBMCs, and its relative inhibition [−28.1% (−69.1 to 
+54.8%)] was significantly less than the inhibition by tacrolimus, 
p < 0.001.
Plasmablast Function (IgM Production and 
Intracellular TNFα Production)
IgM production by donor antigen-stimulated PBMCs was not 
significantly different in PBMCs obtained from the belatacept-
treated patients compared to the tacrolimus-treated patients 
FigUre 5 | Continued  
Belatacept in vitro did not inhibit donor antigen-driven plasmablast formation or TNFα production in a peripheral blood mononuclear cell (PBMC)-based assay, but 
suppressed IgM production. The gating strategy is depicted for plasmablasts (CD19+CD27+CD38++) after 7 days of donor antigen stimulation, in the presence or 
absence of belatacept and tacrolimus (a). Donor PBMCs were discriminated by carboxyfluorescein succinimidyl ester labeling them prior to the mixed lymphocyte 
reaction and gating them out after. The proportions of plasmablasts are shown for 7-day donor antigen-stimulated PBMCs obtained from the belatacept or 
tacrolimus group (“in vivo” column), as well as the relative inhibitions by in vitro addition of belatacept or tacrolimus (“additional in vitro” column) (B). The IgM 
concentrations in the supernatants are shown for the same cultures as previously mentioned (“in vivo” column), as well as the relative inhibitions by in vitro addition 
of belatacept or tacrolimus (“additional in vitro” column) (c). A typical example is depicted for intracellular TNFα-production by plasmablasts after 7 days of donor 
antigen stimulation, in the presence or absence of belatacept (D). The proportions of TNFα+ cells within plasmablasts (e) and the proportions of TNFα+ plasmablasts 
within B-cells (F) are shown for 7-day donor antigen-stimulated PBMCs obtained from the belatacept or tacrolimus group (“in vivo” column), as well as the relative 
inhibitions by in vitro addition of belatacept (“additional in vitro” column). The proportions of TNFα+ plasmablasts could not be reliably determined in the presence of 
tacrolimus in vitro, because of the strong inhibition of plasmablast formation by tacrolimus. In the graphs in the “In vivo drug” columns, every dot represents PBMCs 
of a single patient. In the graphs in the “additional in vitro drug” columns, the relative inhibitions by additional in vitro belatacept and tacrolimus are depicted for 
aforementioned cell populations in the same belatacept- and tacrolimus-treated patients. The proportions of these cell populations after donor antigen stimulation in 
the absence of in vitro drugs are set to 0. The median relative inhibitions by belatacept and tacrolimus were tested against a theoretical median of 0. Asterisks below 
boxes depict the p-values of these tests. The relative inhibitions were compared between in vitro belatacept and tacrolimus. Lines in boxes represent medians, 
borders of boxes represent 25th and 75th percentiles, and error bars present 10th and 90th percentiles. Every box represents cultures of PBMCs obtained from 
n = 20 belatacept-treated or n = 20 tacrolimus-treated patients. *p < 0.05, **p < 0.01, ***p < 0.001, NS, not significant. N.B.: The median fluorescence intensity 
slightly decreases in (antigen-) stimulated cells compared to unstimulated cells, partly because of the intracellular staining protocol that was used to determine 
intracellular cytokine expression. Therefore, the gates in the unstimulated and stimulated cells are not exactly the same.
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(Figure  5C, “in  vivo drug” column). The relative inhibitions 
of IgM production by belatacept and tacrolimus in  vitro were 
−32.9% (−100.0 to +59.1%), p <  0.01, and −54.9% (−100.0 
to +141.4%), p <  0.05, respectively (Figures  5C, “additional 
in vitro drug” column). Even though tacrolimus more efficiently 
inhibited plasmablast formation than belatacept, the inhibition 
of IgM production did not significantly differ between these 
two drugs.
Since belatacept is a fusion protein consisting of the Fc-fragment 
of IgG1 (22), total human IgG could not be determined by ELISA. 
No IgG DSA were detected by Luminex in supernatants of the 
MLRs. IgG3 could be detected in eight cultures with donor-
antigen stimulated PBMCs [median 6.6 (4.8–4.3) ng/mL; 5× 
from tacrolimus-treated and 3× from belatacept-treated patients] 
and was −12.3% (−79.3 to + 33.5%) inhibited in these samples by 
tacrolimus or belatacept, p = 0.01 (Figure S2 in Supplementary 
Material). Because of the limited amount of IgG3+ supernatants 
no subgroup analysis per treatment arm was performed.
Of the B-cells that differentiated into plasmablasts 19.4% 
(0.0–66.7%) expressed intracellular TNFα in the PBMCs obtained 
from belatacept-treated patients and 12.7% (3.4–49.1%) in those 
from the tacrolimus-treated patients, p  =  0.34 (Figure  5E, 
“in  vivo” column). The proportions of TNFα+ plasmablasts 
within total B-cells were also similar in PBMCs from belata-
cept- and tacrolimus-treated patients: 1.2% (0.0–4.1%) and 1.7% 
(0.2–10.1%), respectively, p = 0.34 (Figure 5F, “in vivo” column). 
Belatacept did not affect the proportion of TNFα+ within plas-
mablasts nor the proportions of TNFα+ plasmablasts within total 
B-cells (Figures 5E,F, “additional in vitro” column). The propor-
tions of TNFα+ plasmablasts could not be reliably determined in 
the presence of tacrolimus, because of the strong inhibition of 
plasmablast formation by tacrolimus in vitro.
B-Cell Differentiation and Plasmablast Function in an 
Isolated Coculture System
To eliminate the effects of other cell types and cytokines present 
in the PBMC-based assay, we tested the effects of belatacept 
and tacrolimus in an isolated system of antigen-activated 
CXCR5+ Tfh and CD19+CD27+ memory B-cells (Figure S3 
in Supplementary Material). The differentiation of memory 
B-cells into IgM producing plasmablasts was used as read out. 
Plasmablast formation of 13.2% (2.1–44.9%) was decreased by 
the addition of belatacept to 1.7% (1.3–4.2%), and by tacrolimus 
to 0.5% (0.1–0.9%), both p < 0.05 (Figure S3D in Supplementary 
Material). Tacrolimus more potently inhibited the plasmablast 
formation than belatacept, p < 0.05. The same pattern was seen 
in the IgM production of 253.8  ng/mL (86.5–541.5  ng/mL) 
(Figure S3E in Supplementary Material). Belatacept decreased 
IgM production to 18.1 ng/mL (13.7–68.4 ng/mL), and tacroli-
mus to 6.2 ng/mL (2.2–8.6 ng/mL) (both p < 0.05; tacrolimus 
vs. belatacept p < 0.05).
Immune Regulatory Phenotype (IL-10+ Transitional 
B-Cell Survival)
The presence of B-cells with a regulatory phenotype, i.e., IL10+ 
transitional B-cells, was assessed after donor antigen stimula-
tion in the presence or absence of belatacept or tacrolimus 
(Figure 6).
In unstimulated, uncultured PBMCs the proportions of transi-
tional B-cells were below 3% in both treatment groups (Figure 5B, 
“in  vivo drug” column). After donor antigen stimulation, an 
increase in the proportion of transitional B-cells was observed 
in PBMCs from belatacept- and tacrolimus-treated patients, to 
2.1% (0.0–8.2%), p <  0.01, and 3.0% (0.0−24.7%), p <  0.001, 
respectively (Figure 5B, “in vivo drug” column). The survival of 
these transitional B-cells was not different between the belatacept 
and tacrolimus groups. The in vitro addition of tacrolimus, how-
ever, diminished transitional B-cell survival [relative inhibition: 
−55.4% (−91.4 to −15.1%), p < 0.001], while belatacept did not 
affect the survival of these potentially regulatory B-cells [relative 
inhibition: −27.2% (−100.0 to +247.4%), p = 0.54], tacrolimus vs. 
belatacept, p < 0.05.
Both the transitional B-cells in the PBMCs obtained from 
belatacept-treated patients as those from tacrolimus-treated 
patients expressed IL-10 after donor antigen stimulation: MFI 617 
(397 to 1577) and MFI 666 (297 to 1697), respectively, p = 1.00 
FigUre 6 | Transitional B-cells and their donor antigen-driven IL-10 production were conserved by belatacept in vitro but inhibited by tacrolimus. The gating 
strategy is depicted for transitional B-cells (CD24+CD38++) after donor antigen stimulation (a). Cells were gated from CD19+ B-cells like depicted in Figure 4a.  
The proportions of transitional B-cells are shown for 7-day donor antigen-stimulated peripheral blood mononuclear cells (PBMCs) obtained from the belatacept or 
tacrolimus group (“in vivo” column), as well as the relative inhibitions by in vitro addition of belatacept or tacrolimus (“additional in vitro” column) (B). A typical 
example is depicted for intracellular IL-10 expression [median fluorescence intensity (MFI)] by transitional B-cells after 7 days of donor antigen stimulation, in the 
presence or absence of belatacept, including a Fluorescence-Minus-One control (FMO) (c). The MFIs of IL-10 within transitional B-cells are shown for 7-day donor 
antigen-stimulated PBMCs obtained from the belatacept or tacrolimus group (“in vivo” column), as well as the relative inhibitions by in vitro addition of belatacept 
(“additional in vitro” column) (D). The MFI of IL-10 within transitional B-cells could not be reliably determined in the presence of tacrolimus in vitro, because of the 
decreased transitional B-cells survival in the presence of tacrolimus. In the graph in the “In vivo drug” column in (B), proportions of transitional B-cell populations 
were compared (i) between belatacept- and tacrolimus-treated patients in uncultured, unstimulated PBMCs; (ii) between belatacept- and tacrolimus-treated patients 
in 7-day donor antigen stimulated PBMCs; (iii) between uncultured, unstimulated PBMCs and 7-day donor antigen stimulated PBMCs in belatacept-treated patients; 
and (iv) between uncultured, unstimulated PBMCs and 7-day donor antigen stimulated PBMCs in tacrolimus-treated patients. Every dot represents PBMCs of a 
single patient. In the graphs in the “Additional in vitro drug” column the relative inhibitions by additional in vitro belatacept and tacrolimus are depicted for 
aforementioned cell populations in the same belatacept- and tacrolimus-treated patients. The proportions of these cell populations after donor antigen stimulation in 
the absence of in vitro drugs are set to 0. The median relative inhibitions by belatacept and tacrolimus were tested against a theoretical median of 0. Asterisks below 
boxes depict the p-values of these tests. The relative inhibitions were compared between in vitro belatacept and tacrolimus. Lines in boxes represent medians, 
borders of boxes represent 25th and 75th percentiles, error bars present 10th and 90th percentiles. Every box represents cultures of PBMCs obtained from n = 20 
belatacept-treated or n = 20 tacrolimus-treated patients. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, NS, not significant. N.B.: The MFI slightly decreases in 
antigen-stimulated cells compared to unstimulated cells, partly because of the intracellular staining protocol that was used to determine intracellular cytokine 
expression. Therefore, the gates in the unstimulated and stimulated cells are not exactly the same.
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(Figure 6D, “in vivo” column). Belatacept in vitro did not decrease 
IL-10 production in transitional B-cells (Figure 6D, “additional 
in vitro” column). The MFI of IL-10 within transitional B-cells 
could not be reliably determined in the presence of tacrolimus, 
because of the decreased transitional B-cells survival in the pres-
ence of tacrolimus in vitro.
TaBle 1 | The effect of belatacept in vitro on free CD86 expression on B-cells, plasmablast formation, and transitional B-cell survival.
Dependent variable independent variables Beta se p
CD86 expressing naïve B-cells (% CD86+ of CD19+CD27− B-cells) Belatacept added in vitro (vs. tacrolimus added in vitro) −4.53 2.85 0.12
PBMCs obtained after transplantation (vs. before transplantation) 1.76 2.50 0.48
PBMCs obtained from rejector (vs. non-rejector) −0.09 3.02 0.98
Proportion of cell subset without in vitro drugs added 0.55 0.06 0.00
CD86 expressing memory B-cells (% CD86+ of CD19+CD27+ B-cells) Belatacept added in vitro (vs. tacrolimus added in vitro) −9.34 2.84 0.02
PBMCs obtained after transplantation (vs. before transplantation) −1.15 2.49 0.65
PBMCs obtained from rejector (vs. non-rejector) 2.10 3.01 0.49
Proportion of cell subset without in vitro drugs added 0.61 0.07 0.00
Plasmablasts (% CD27+CD38++ of CD19+ B-cells) Belatacept added in vitro (vs. tacrolimus added in vitro) 4.45 1.28 0.00
PBMCs obtained after transplantation (vs. before transplantation) −1.57 1.08 0.15
PBMCs obtained from rejector (vs. non-rejector) 2.34 1.32 0.08
Proportion of cell subset without in vitro drugs added 0.66 0.07 0.00
Transitional B-cells (% of CD19+ B-cells) Belatacept added in vitro (vs. tacrolimus added in vitro) −0.09 −0.01 0.91
PBMCs obtained after transplantation (vs. before transplantation) −0.38 0.71 0.59
PBMCs obtained from rejector (vs. non-rejector) 0.40 0.86 0.65
Proportion of cell subset without in vitro drugs added 0.24 0.07 0.00
A multivariable regression analysis was performed per cell subset with as dependent variable the value after donor antigen stimulation plus in vitro drugs (belatacept or tacrolimus) 
and as independent variables addition of in vitro belatacept (vs. in vitro tacrolimus), the time point PBMCs were obtained (after vs. before transplantation), PBMCs obtained during 
rejection (rejector vs. non-rejector) and the value after donor antigen stimulation without in vitro drugs added. Statistically significant p-values (<0.05) are underscored.
Proportions of the different donor antigen-stimulated subsets without in vitro drugs added were most predictive for the proportions in the presence of in vitro drugs. In 11 belatacept-
treated patients and 2 tacrolimus-treated patients the PBMCs were obtained during acute rejection, before additional anti-rejection therapy was given. Obtaining PBMCs from 
patients who rejected or time point the PBMCs were obtained (before or after transplantation) were not predictive for the proportions of these cells.
PBMCs, peripheral blood mononuclear cells; Rejector vs. non-rejector, patients who rejected vs. patients who did not reject within 12 months after transplantation (biopsy-proven); 
SE, standard error of beta.
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Summary of the Effects of Belatacept and Tacrolimus 
on B-Cells
Donorantigen-driven CD86 upregulation was not fully inhibited 
by belatacept, especially on memory B-cells, even by suprathera-
peutic doses of belatacept. In contrast to tacrolimus, belatacept 
could not inhibit donorantigen-driven plasmablast formation in 
a PBMC-based assay but only in an isolated Tfh-B-cell coculture. 
Also in the latter, belatacept was less effective than tacrolimus. The 
survival of the potentially immune regulatory IL-10+ transitional 
B-cells was, however, not affected by belatacept, while this was 
diminished by tacrolimus.
redundancy of the immune system
The Effect of Belatacept and Tacrolimus on 
Redundant Co-Stimulatory Pathways
To explain why belatacept did not inhibit plasmablast formation 
in our PBMC studies, and because patients’ cellular interactions 
are influenced by redundant and pleiotropic mechanisms of 
immune cells, surface receptors of other costimulatory pathways 
were measured (Figure S4 in Supplementary Material).
In PBMCs from three belatacept-treated and three 
tacrolimus-treated patients, the ICOS-ICOSL, PD-1-PD-L1, 
and the CD40L-CD40 pathways were studied after donor 
antigen stimulation Expressions of all surface molecules, except 
for CD28 and ICOSL, were increased on Tfh and B-cells after 
donor antigen stimulation (Figures S4A,C in Supplementary 
Material). The upregulation of the costimulatory molecules 
on Tfh-cells was not fully suppressed by belatacept and to a 
lesser extent than by tacrolimus (Figure S4 in Supplementary 
Material).
Multivariable regression analyses
The Effect of Belatacept and Tacrolimus in Vitro  
on Tfh- and B-Cells
The effect of belatacept in  vitro was compared to the effect of 
tacrolimus in  vitro in multivariable regression analyses for 
proportions of CD86+ naïve and memory B-cells, plasmablast 
formation, and transitional B-cell survival (adjusted for the vari-
ables as stated in Table 1). These cell subsets were chosen, because 
they significantly differed when belatacept was added compared 
to tacrolimus in  vitro (Figures  4–6). Multivariable analyses 
confirmed that belatacept and tacrolimus differed in inhibition of 
plasmablast formation: plasmablast formation was 4.5% (SE 1.3) 
higher in the presence of belatacept than in the presence of 
tacrolimus in  vitro, p =  0.001 (Table  1). In the multivariable 
analysis, transitional B-cell survival (defined as the proportion of 
transitional B-cells of total B-cells) was not significantly higher 
in the presence of belatacept compared to in  vitro addition 
of tacrolimus (p =  0.91). Finally, the free CD86 expression on 
CD27+ memory B-cells was 9.3% (SE 2.8) lower when the donor 
antigen-stimulated PBMCs were spiked with belatacept in vitro 
compared to tacrolimus in  vitro, p =  0.001, but no significant 
difference was found for free CD86-expression on the surface of 
naïve B-cells (p = 0.12).
Peripheral blood mononuclear cells were obtained 3 months 
after transplantation in non-rejectors, and during rejection before 
additional anti-rejection therapy was given in rejectors. Eleven of 
twenty belatacept-treated patients and two of twenty tacrolimus-
treated patients developed a BPAR. Obtaining PBMCs during 
acute rejection did not alter the in vitro reaction to donor antigen 
or drug (Table 1).
TaBle 2 | Effects of belatacept and tacrolimus in vitro on donor antigen-activated follicular T-helper (Tfh) and B-cells.
immunological reaction Defined by effect by belatacept 
in vitro
effect by tacrolimus 
in vitro
comparison belatacept vs. 
tacrolimusa
Tfh-cell generation CXCR5 expression ↑ on CD4+ 
T-cells
Inhibition (minimal) Inhibition (minimal) bela = tac
Tfh-cell activation PD-1 expression ↑ on 
CD4+CXCR5+ T-cells
Inhibition (partial) Inhibition (partial) bela = tac
Activated Tfh-cell generation CXCR5+PD-1+ double expression 
↑ on CD4+ T-cells
Inhibition (partial) Inhibition (partial) bela = tac
IL-21+-activated Tfh-cell generation The proportion of IL-21+ 
CXCR5+PD-1+ ↑ within CD4+ 
T-cells
Inhibition (partial) Inhibition (partial) bela = tac
IL-21 production by activated 
Tfh-cells
Intracellular IL-21 expression of 
CXCR5+PD-1+ CD4+ T-cells
None Inhibition (minimal) bela = tac
B-cell activation CD86 expression ↑ on B-cells Inhibition (partial) Inhibition (partial) bela is more efficient than tacb
Transitional B-cell survival The proportion of CD24+CD38++ 
B-cells
None Inhibition (partial) bela is more benificial than tacc
Plasmablast formation Proportion of B-cells differentiated 
into CD27+CD38++ B-cells
In PBMCs: none In PBMCs: inhibition (partial) bela is less efficient than tacd
In isolated system with 
Tfh- and B-cells: inhibition 
(almost completely)
In isolated system with 
Tfh- and B-cells: inhibition 
(completely)
bela is slightly less efficient 
than tac
IgM production Total IgM in supernatant of 
cocultures
In PBMCs: inhibition (partial) In PBMCs: inhibition (partial) bela = tac
In isolated system with 
Tfh- and B-cells: inhibition 
(almost completely)
In isolated system with 
Tfh- and B-cells: inhibition 
(completely)
bela is slightly less efficient 
than tac
bela, belatacept; IgM, immunoglobulin M; PBMCs, peripheral blood mononuclear cells; tac, tacrolimus.
aComparison of the relative inhibition by belatacept in vitro and tacrolimus in vitro.
bThese observations were confirmed in a multivariable regression analysis for memory B-cells, but not for naïve B-cells (Table 1).
cThese observations were not confirmed in a multivariable regression analysis (Table 1).
dThese observations were confirmed in a multivariable regression analysis (Table 1).
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A first explanation for these findings is the differences between 
our study and previous work (14, 23, 24). Belatacept has always been 
compared to CsA and not with the more potent tacrolimus and used 
in combination with other types of immunosuppressive agents, 
such as T-cell depleting therapy or mTOR inhibition in the animal 
studies (14, 23) or MMF and prednisone in the BENEFIT trial (24). 
The study presented here reports on the isolated effects of belatacept 
and tacrolimus on the functional interaction of patient-derived Tfh- 
and B-cells. These differences might have led to an overestimation 
of the inhibition of Tfh–B-cell interaction by belatacept, not taking 
into account the effects of other immunosuppressive agents.
A second reason could be the significant residual expression 
of CD86 on donor antigen-activated B-cells, even in the presence 
of supratherapeutic concentrations of belatacept. This might be 
explained by (1) a lower affinity of belatacept for donor antigen-
activated CD86 molecules on B-cells, (2) a higher turnover of CD86 
by B-cells, or (3) degradation of belatacept during the 7-day cultures. 
The latter is unlikely, since CD80 was efficiently blocked by belatacept. 
Until the study presented here, the efficacy of belatacept on occupy-
ing CD86 had only been studied on monocyte-derived dendritic cells 
(DCs) and not on B-cells (41). As a result of the incomplete blockade 
of CD86 on B-cells, activation and consequently differentiation of 
B-cells were not prevented by costimulation blockade. The produc-
tion of IgM was, however, inhibited by belatacept (median ~50%), 
possibly because CD80 blockade or partial CD86 blockade also 
The effects of belatacept and tacrolimus in vitro on the different 
Tfh- and B-cell subsets are summarized in Table 2.
DiscUssiOn
In this study, the effects of belatacept on Tfh–B-cell interaction 
were compared to those of tacrolimus for the first time in kidney 
transplant patients. No differences were observed in unstimulated 
uncultured PBMCs or donor antigen-stimulated PBMCs obtained 
from belatacept- or tacrolimus-treated patients, which may be 
explained by the predominant effects by MMF and prednisone in 
both regimens. Therefore, the isolated effects of in vitro belatacept 
and tacrolimus were compared. In vitro addition of both drugs only 
minimally inhibited Tfh-cell generation and partially decreased 
activation of Tfh-cells (defined by PD-1 upregulation). Activated 
Tfh-cells produced the highest levels of IL-21, and the total propor-
tion of IL-21+ activated Tfh-cells in the presence of in vitro immuno-
suppression was also partially reduced. Still, IL-21 production and 
B-cell help by remaining Tfh-cells were sufficient in the presence 
of in vitro belatacept, because the donor antigen-driven formation 
of plasmablasts in our MLR-based PBMC assay was not inhibited 
by the costimulation blocker, in contrast to in vivo observations in 
animal studies (14, 23). These newly formed TNFα+ plasmablasts, 
that have been associated with aggressive reactivity in autoimmun-
ity (42), were suppressed in the presence of tacrolimus.
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leads to impaired immunoglobulin responses (43, 44). Nonetheless, 
belatacept was not more efficient than tacrolimus in preventing IgM 
production and even slightly less efficient in an isolated system. The 
lower percentage of DSA-positive patients in the belatacept than in 
the CsA group in the BENEFIT trial (24) could be (1) a reflection of 
better compliance in the first group (45, 46), (2) the lower potency 
of CsA compared to tacrolimus (25), and (3) higher concentrations 
of mycophenolate acid in the first group (47, 48).
A third answer can be found in redundant costimulatory 
pathways taking over during costimulation blockade of the 
CD28-CD80/86 pathway. Because belatacept affects only this path-
way (22), other costimulatory pathways, such as CD40-CD40L 
and ICOS-ICOSL, may “bypass” blockade of CD28-CD80/86. In 
our small cohort study of n =  6 independent experiments, the 
upregulation of CD40L and ICOS on Tfh-cells were less reduced 
by belatacept than by tacrolimus, making these cells more capable 
of helping B-cells. Since tacrolimus has a direct effect on T- and 
B-cells by inhibiting calcineurin downstream the surface recep-
tors (27, 29, 49), its effect is not dependent on costimulation 
blockade. Further studies that test the combination of belatacept 
with CD40- or ICOS-blockade could confirm this hypothesis but 
were beyond the scope of the study presented here.
A final possibility is that belatacept less effectively inhibits DCs and 
their interaction with Tfh- and B-cells than the interaction between 
Tfh- and B-cells, especially in an in vitro setting in the absence of 
a germinal center (50–52). Unlike in donor antigen-stimulated 
PBMCs, in an isolated system of pure CXCR5+ Tfh and memory 
B-cells, belatacept successfully inhibited plasmablast formation. A 
big difference between PBMCs and isolated Tfh and memory B-cells 
is the absence of patient DCs and their antigen-presenting function 
in the isolated system, i.e., the absence of the indirect and semidirect 
pathways of antigen presentation (53). The effect of belatacept on 
human DCs is not yet studied and a lack hereof could explain the 
less efficient inhibition by belatacept on Tfh–B-cell interaction. 
Nevertheless, donor DCs, facilitating the direct pathway for antigen 
presentation, were still present in the isolated system. This sug-
gests belatacept effectively inhibits the direct, but not the indirect 
or semidirect pathways of antigen presentation. Absence of other 
cells, like natural killer cells, could also be an explanation for the 
successful inhibition by belatacept in the isolated system. We believe 
a PBMC-based assay is more similar to the milieu in patients than 
an isolated cell assay, because in the first system, multiple cell types 
and redundant pathways are of importance.
It should be noted almost no IgG3 by ELISA and no anti-HLA 
IgGby Luminex were detected in the culture supernatants, pos-
sibly because only materials of immunologically low-risk patients 
were used. Since belatacept is an IgG1, it cannot be ruled out that 
IgG1 antibodies were present in the cocultures’ supernatants. 
Another limitation of this study is that anti-CD86 monoclonal 
antibodies that are non-competitive to belatacept and bind to 
another epitope than belatacept are not commercially available 
(41). The total CD86 expression, irrespective of saturated CD86 
by belatacept in the cocultures, could therefore not be determined.
A possible beneficial consequence of the incomplete inhibition 
of B-cells by costimulation blockade is that belatacept favored the 
(potentially regulatory) IL-10+ transitional B-cell survival, while 
this was diminished by tacrolimus (30–32). However, these findings 
were not confirmed by multivariable regression analyses. Therefore, 
the clinical relevance of these observations needs to be validated 
in a larger population. Even more, since (1) most rejections occur 
within the first months after transplantation, when glucocorticoids 
are still used and negatively influence transitional B-cell survival 
(30) and (2) the regulatory capacities of antigen-specific transitional 
B-cells have not yet been confirmed in functional studies in humans. 
Another favorable outcome of incomplete Tfh-B-cell inhibition by 
belatacept could be a lower infection risk and more potent vaccine 
responses in belatacept-treated patients than in tacrolimus-treated 
patients. So far no evidence for this emerged from previous studies 
nor has it been confirmed in randomized-controlled trials compar-
ing belatacept and CNI-treated patients (24, 54–56).
In this functional study, belatacept was less potent than tacroli-
mus in inhibiting donor antigen-driven plasmablast formation.
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